Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:185:105-126.
doi: 10.1007/978-3-031-27156-4_7.

Oncolytic Virotherapy

Munazza Fatima  1 , Deeba Amraiz  2 , Muhammad Tariq Navid  1
Affiliations

Oncolytic Virotherapy

Munazza Fatima et al. Cancer Treat Res. 2023.

Abstract

Oncolytic virotherapy opens up avenues for cancer treatment by selectively targeting the cancer cells and destructs them either through direct lysis or by inducing an immune response in the tumor microenvironment. This platform technology utilizes a diverse range naturally existing or genetically modified oncolytic viruses for their immunotherapeutic potential. Due to the limitations associated with the conventional cancer therapies, immunotherapies using oncolytic viruses (OVs) have generated a great deal of interest in the modern era. Currently, several oncolytic viruses have entered clinical trials and have proven successful for a number of different cancers as monotherapies as well as in combination with the standard treatment methods like chemotherapy, radiotherapy, or immunotherapy. Efficacy of OVs can be further enhanced by utilizing several approaches. Efforts of the scientific community for getting better knowledge of individual patient tumor immune responses will enable medical community to treat cancer patients more precisely. In this regard, OV seems to be a part of multimodality cancer treatment option in the near future. In this chapter, the fundamental characteristics and mechanism of actions of oncolytic viruses are initially described and then overview of the important clinical trials of various oncolytic viruses for a number of cancers is presented.

Keywords: Cancer therapy; Clinical trials; Immunotherapy; Oncolytic viruses.

PubMed Disclaimer

References

    1. Andtbacka RHI, Collichio F, Harrington KJ, Middleton MR, Downey G et al (2019) Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. J Immunother Cancer 7:145. https://doi.org/10.1186/s40425-019-0623-z - DOI - PubMed - PMC
    1. Axelrod ML, Cook RS, Johnson DB, Balko JM (2019) Biological consequences of MHC-II expression by tumor cells in cancer. Clin Cancer Res 25:2392–2402 - PubMed - DOI
    1. Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P (2020) Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal 18:59. https://doi.org/10.1186/s12964-020-0530-4 - DOI - PubMed - PMC
    1. Barry MA, Weaver EA, Chen CY (2012) Mining the adenovirus “Virome” form systemic oncolytics. Curr Pharm Biotechnol 13:1804–1808 - PubMed - DOI
    1. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, Mccormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373–376

LinkOut - more resources